Glasdegib

Last Updated: 11/08/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications

A One-Min, FDA-Validated UPLC-MS/MS Method for the AML Smoothened Inhibitor Glasdegib Quantification and Metabolic Stability Assessment in Human Liver Microsomes: In Silico Metabolic Lability and Toxicity Screening.

A One-Min, FDA-Validated UPLC-MS/MS Method for the AML Smoothened Inhibitor Glasdegib Quantification and Metabolic Stability Assessment in Human Liver Microsomes: In Silico Metabolic Lability and Toxicity Screening.

Journal: Biomedical chromatography : BMC
Published: August 02, 2026

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.

Journal: Journal of managed care & specialty pharmacy
Published: July 27, 2026

Glasdegib and inotuzumab ozogamicin in B-cell acute lymphoblastic leukemia: Assessing drug responses in a stromal co-culture model.

Glasdegib and inotuzumab ozogamicin in B-cell acute lymphoblastic leukemia: Assessing drug responses in a stromal co-culture model.

Journal: Biomolecules & biomedicine
Published: May 08, 2026

Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.

Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.

Journal: Annals of hematology
Published: January 06, 2026

Dual Hedgehog/GLI1 and PI3K/Akt/mTOR Targeting Possesses Higher Efficacy to Inhibit T-Cell Acute Lymphoblastic Leukemia Growth.

Dual Hedgehog/GLI1 and PI3K/Akt/mTOR Targeting Possesses Higher Efficacy to Inhibit T-Cell Acute Lymphoblastic Leukemia Growth.

Journal: Cells
Published: October 30, 2025

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Journal: Cells
Published: August 15, 2025

Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.

Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.

Journal: Future oncology (London, England)
Published: June 10, 2025

A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer.

A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer.

Journal: Anticancer research
Published: May 06, 2025

Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices.

Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices.

Journal: Expert review of hematology
Published: April 17, 2025

Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial.

Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial.

Journal: Nature communications
Published: March 12, 2025

Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis.

Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis.

Journal: Investigational new drugs
Published: February 04, 2025

Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis.

Gastrointestinal adverse events associated with Hedgehog pathway inhibitors: a disproportionality analysis.

Journal: The International journal of pharmacy practice
Published: November 13, 2024
Showing 1-12 of 131

Last Updated: 11/08/2026